Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS Watch Within the Next 24 hrs - They Keep Trying To Hide This!!!
Patriots Base Published November 2, 2022
https://rumble.com/v1r0uum-watch-within-the-next-24-hrs-they-keep-trying-to-hide-this.html
*Live* Donald J. Trump’s SAVE AMERICA rally.
President Donald J. Trump, 45th President of the United States of America, will hold a rally in Sioux City, Iowa on Thursday, November 3, 2022, at 7:00PM CDT.
Thursday, November 3, 2022, at 7:00PM CDT ...
((( WILL WE SEE HIS NEW PLANE @ THIS AIRPORT ))) ??
https://www.rsbnetwork.com/category/video/donald-trump/
THE RETURN OF NETANYAHU, ELON'S TWITTER CENSORS, DEFINITION OF ANTI-SEMITISM, KYRIE CONDEMNED | KMN
WATCH
https://www.bitchute.com/video/JcpJIA9wDx2z/
GREAT WATCH LIVE: PRESIDENT DONALD J. TRUMP HOLDS RALLY IN MIAMI, FL – 11/6/22
by RSBN
Sunday, November 6, 2022: Join the RSBN broadcast crew LIVE from Miami, FL
for all day coverage of President Donald J. Trump’s “Get Out the Vote Rally” with
Senator Marco…
https://www.rsbnetwork.com/category/video/donald-trump/
NWO The blame game -
GENETIC ENGINEERING BIOWEAPON EXPOSED: NANO-STRUCTURES IN THE DEATH JAB
WATCH
https://www.bitchute.com/video/xs7kfJ9w1Dbw/
BEWARE; A number of faith leaders have insisted that Jesus himself would get the jab, were
He here today.
But not once did Jesus advise people to rely on the tools — or
word — of man. Instead, He warned of a future time when even the elect will fall
prey to a grand deception
Hindsight, scientific evidence and statistical data allow us to conclude that many
faith leaders led their flocks astray.
The COVID shot does not protect you from
infection and death, nor does it protect anyone else. It was all a lie, and excess
death rates skyrocketed after the rollout of the COVID shots
https://articles.mercola.com/sites/articles/archive/2022/10/31/faith-leaders-promotes-covid-vaccine.aspx?ui=f31c52a3f8937693fc4daf3324ea789acdff1bba8274a31b5972577e0424a49d&sd=20150920&cid_source=dnl&cid_medium=email&cid_content=art1HL&cid=20221031&cid=DM1276919&bid=1633441104
Russia and Iran, New "Axis of Evil," Emboldened by Biden Administration
by Majid Rafizadeh
October 29, 2022 at 5:00 am
https://www.gatestoneinstitute.org/19051/russia-iran-evil-emboldened
ROUBINI WARNS OF IMMINENT DOLLAR CRASH
WATCH
https://www.bitchute.com/video/FuUBZ2VNzBeh/
BRICS | Is the Collapse of the Dollar Around the Corner? 15 Questions We All
Need to Be Asking About the Future Value of the U.S. Dollar (Andrew Sorchini
with Clay Clark)
https://www.brighteon.com/111d6525-f68c-4df1-9186-cc4a586af0f4
DOLLAR TO COLLAPSE! - SAUDI ARABIA TO LEAVE DOLLAR FOR BRICS! - MASSIVE POWER SHIFT!
WATCH
https://www.bitchute.com/video/O9ky2nStDghK/
Thanks Al44
ARIS Great Gold Producer;
https://seekingalpha.com/article/4527727-aris-gold-gcm-mining-merger-makes-sense
Aris Mining Corporation (Aris Mining) (TSX: ARIS) (OTCQX: TPRFF)
Great Gold, Global Population And Propaganda
https://kingworldnews.com/gold-global-population-and-propaganda/
$370 Silver Target, Plus Major Economic Trend Forecasts Issued By Gerald Celente
October 26, 2022
https://kingworldnews.com/370-silver-target-plus-major-economic-trend-forecasts-issued-by-gerald-celente/
Aris Mining Corporation (Aris Mining) (TSX: ARIS) (OTCQX: TPRFF) Highest
Close in 2 Weeks on the ARIS;
The $3.04 close is the highest since October 13th. Maybe the jaded seller
lamenting the loss of the dividend is sold out? With the US dollar index closing
below its 50 dma today, Gold may continue higher and bring a lift to the PM sector.
There are 556,000 shares short as of October 14th (per yahoo finance), which is 3
days of average trading volume. If they were smart, the covered under $3.
We should see the 3Q earnings report next month. I am hoping for a definitive
gold production forecast for 2023 and 2024. Marmato underground operations
and the mill capacity up grade at Segovia from 1500 to 2000 tpd, are near term
drivers for the company.[/b[
by tobinator01 (sth)
Aris Mining appoints Mónica de Greiff as a member of the Board of Directors
October, 04, 2022
VANCOUVER, BC, Oct. 4, 2022 /PRNewswire/ -
Aris Mining Corporation (Aris Mining) (TSX: ARIS) (OTCQX: TPRFF) announces
that, effective October 1, 2022, Mónica de Greiff was appointed as an
independent member of the Board of Directors, and as Chair of the Sustainability
Committee of the Board.
ARIS Mining (CNW Group/Aris Mining Corporation)
Mónica de Greiff was a member of the GCM Mining board of directors from 2018 to 2020, when she left to accept the position of Colombian Ambassador to Kenya. She has held positions in both the public and private sectors, including as Minister of Justice for the Republic of Colombia and Vice Minister of Mines and Energy. Ms. de Greiff is also a former member of the Board of Directors of the United Nations Global Compact, the world's largest corporate sustainability initiative.
Ian Telfer, Chair of Aris Mining, stated "I am delighted to welcome Mónica to our Board of Directors. She brings considerable experience within Colombia and in the highly valued and important area of sustainability. We look forward to her contributions to our business as we continue to grow and enhance our commitment towards ESG."
About Aris Mining
Aris Mining is a Canadian company led by an executive team with a track record
of creating value through building globally relevant mining companies.
In Colombia, Aris Mining operates several high-grade underground mines at its
Segovia Operations and the Marmato Mine, which together produced 230,000
ounces of gold in 2021.
Aris Mining also operates the Soto Norte joint venture, where environmental
licensing is advancing to develop a new underground gold, silver and copper
mine. In Guyana, Aris Mining is advancing the Toroparu Project, a gold/copper
project with expected average gold production of 225,000 per year over the life of
mine. Aris Mining plans to pursue acquisition and other growth opportunities to unlock value creation from scale and diversification.
Aris Mining promotes the formalization of small-scale mining as this process
enables all miners to operate in a legal, safe and responsible manner that protects
them and the environment.
Additional information on Aris Mining can be found at
http://www.aris-mining.com
and www.sedar.com.
https://www.aris-mining.com/operations/operating-mines/segovia/overview/default.aspx
https://www.aris-mining.com/investors/events-and-presentations/default.aspx
https://www.aris-mining.com/news/news-details/2022/Aris-Mining-appoints-Mnica-de-Greiff-as-a-member-of-the-Board-of-Directors/default.aspx
CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/aris-mining-appoints-monica-de-greiff-as-a-member-of-the-board-of-directors-301640112.html
SOURCE Aris Mining Corporation
VIEW ALL NEWS
GCM Mining Corp. (formerly Gran Colombia Gold)
(TSX: GCM / OTCQX: TPRFF)
Accretive Acquisition to Drive Valuation Higher
BUY
https://www.researchfrc.com/wp-content/uploads/2022/08/GCM-Aug-2022-Update-1.pdf?vgo_ee=TMO54WfXmKl1gA%2FTEb1O1%2FlMy%2BOWWuyaZunZiCXh6gI%3D
Current Price: C$3.35
Fair Value: C$10.09
Risk: 3
GCM Mining Corp. PowerPoint Presentation
https://s28.q4cdn.com/389315916/files/doc_downloads/2022/07/Aris-Gold-GCM-presentation-25-July-2022.pdf
$In GOD We Trust - Real Money - AU Safety 6000yrs )
https://www.kitconet.com/images/quotes_7a.gif?1493417496003
https://www.kitco.com/images/live/silver.gif?0.8344882022363285
Gold & Silver is the only REAL Legal Tender -
by The Founding Fathers for your -
Rights, Liberty and Freedom -
http://www.biblebelievers.org.au/monie.htm
GOLD STANDARD; THE REAL LEGAL MONEY:
https://www.cs.mcgill.ca/~rwest/wikispeedia/wpcd/wp/g/Gold_standard.htm#:~:text=Advocates%20of%20a%20variety%20of,basis%20for%20a%20monetary%20system.
https://www.usdebtclock.org/
https://www.worldometers.info/coronavirus/country/us/
https://www.whatdoesitmean.com/index.htm
God Bless.America
https://www.silverdoctors.com/headlines/world-news/u-s-dollar-to-collapse-saudi-arabia-to-leave-the-dollar-for-brics-in-massive-power-shift/
CT Follow The Patriot Base;
https://rumble.com/c/KPB
Supreme Court Blocks Congress From Getting Trump's Tax Returns
Tyler Durden's Photo
BY TYLER DURDEN
TUESDAY, NOV 01, 2022 - 11:00 AM
Authored by Zachary Stieber via The Epoch Times,
The U.S. Supreme Court on Nov. 1 blocked Congress from obtaining former President Donald Trump’s tax returns.
Chief Justice John Roberts, a George W. Bush appointee, stayed an appeals court order that had ruled a congressional panel could gain access to the documents.
https://www.zerohedge.com/markets/supreme-court-blocks-congress-getting-trumps-tax-returns
Aris Mining Corporation (Aris Mining) (TSX: ARIS) (OTCQX: TPRFF)
Low Bargain Close -
We should see the 3Q earnings report Nov. I am hoping for a definitive
gold production forecast for 2023 and 2024.
Marmato underground operations and the mill capacity up grade at Segovia
from 1500 to 2000 tpd, are near term
drivers for the company.
Aris Mining appoints Mónica de Greiff as a member of the Board of Directors
October, 04, 2022
VANCOUVER, BC, Oct. 4, 2022 /PRNewswire/ -
Aris Mining Corporation (Aris Mining) (TSX: ARIS) (OTCQX: TPRFF) announces
that, effective October 1, 2022, Mónica de Greiff was appointed as an
independent member of the Board of Directors, and as Chair of the Sustainability
Committee of the Board.
ARIS Mining (CNW Group/Aris Mining Corporation)
Mónica de Greiff was a member of the GCM Mining board of directors from 2018 to 2020, when she left to accept the position of Colombian Ambassador to Kenya. She has held positions in both the public and private sectors, including as Minister of Justice for the Republic of Colombia and Vice Minister of Mines and Energy. Ms. de Greiff is also a former member of the Board of Directors of the United Nations Global Compact, the world's largest corporate sustainability initiative.
Ian Telfer, Chair of Aris Mining, stated "I am delighted to welcome Mónica to our Board of Directors. She brings considerable experience within Colombia and in the highly valued and important area of sustainability. We look forward to her contributions to our business as we continue to grow and enhance our commitment towards ESG."
About Aris Mining
Aris Mining is a Canadian company led by an executive team with a track record
of creating value through building globally relevant mining companies.
In Colombia, Aris Mining operates several high-grade underground mines at its
Segovia Operations and the Marmato Mine, which together produced 230,000
ounces of gold in 2021.
Aris Mining also operates the Soto Norte joint venture, where environmental
licensing is advancing to develop a new underground gold, silver and copper
mine. In Guyana, Aris Mining is advancing the Toroparu Project, a gold/copper
project with expected average gold production of 225,000 per year over the life of
mine. Aris Mining plans to pursue acquisition and other growth opportunities to unlock value creation from scale and diversification.
Aris Mining promotes the formalization of small-scale mining as this process
enables all miners to operate in a legal, safe and responsible manner that protects
them and the environment.
Additional information on Aris Mining can be found at
http://www.aris-mining.com
and www.sedar.com.
https://www.aris-mining.com/operations/operating-mines/segovia/overview/default.aspx
https://www.aris-mining.com/investors/events-and-presentations/default.aspx
https://www.aris-mining.com/news/news-details/2022/Aris-Mining-appoints-Mnica-de-Greiff-as-a-member-of-the-Board-of-Directors/default.aspx
CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/aris-mining-appoints-monica-de-greiff-as-a-member-of-the-board-of-directors-301640112.html
SOURCE Aris Mining Corporation
VIEW ALL NEWS
GCM Mining Corp. (formerly Gran Colombia Gold)
(TSX: GCM / OTCQX: TPRFF)
Accretive Acquisition to Drive Valuation Higher
BUY
https://www.researchfrc.com/wp-content/uploads/2022/08/GCM-Aug-2022-Update-1.pdf?vgo_ee=TMO54WfXmKl1gA%2FTEb1O1%2FlMy%2BOWWuyaZunZiCXh6gI%3D
Current Price: C$3.35
Fair Value: C$10.09
Risk: 3
GCM Mining Corp. PowerPoint Presentation
https://s28.q4cdn.com/389315916/files/doc_downloads/2022/07/Aris-Gold-GCM-presentation-25-July-2022.pdf
$2.5 Quadrillion Disaster Waiting to Happen – Egon von Greyerz
By Greg Hunter On November 1, 2022 In Market Analysis 98 Comments
https://usawatchdog.com/2-5-quadrillion-disaster-waiting-to-happen-egon-von-greyerz/
$In GOD We Trust - Real Money - AU Safety 6000yrs )
https://www.kitconet.com/images/quotes_7a.gif?1493417496003
https://www.kitco.com/images/live/silver.gif?0.8344882022363285
Gold & Silver is the only REAL Legal Tender -
by The Founding Fathers for your -
Rights, Liberty and Freedom -
http://www.biblebelievers.org.au/monie.htm
GOLD STANDARD; THE REAL LEGAL MONEY:
https://www.cs.mcgill.ca/~rwest/wikispeedia/wpcd/wp/g/Gold_standard.htm#:~:text=Advocates%20of%20a%20variety%20of,basis%20for%20a%20monetary%20system.
https://www.usdebtclock.org/
https://www.worldometers.info/coronavirus/country/us/
https://www.whatdoesitmean.com/index.htm
God Bless.America
Preciouslife1; FDA MURDERED 500K AMERICANS; FORMER TRUMP ADMIN OFFICIAL SAYS THE FDA BLOCKED AMERICANS FROM LIFE-SA?
WATCH
https://www.bitchute.com/video/MR0szdGNmyXT/
Big Pharma Set To Control Entire Food Supply
Patriots Base Published October 23, 2022
https://rumble.com/v1pel2j-big-pharma-set-to-control-entire-food-supply.html
Past and present thanks; ***Dr. Leland Stillman - How Conventional Medicine Kills, and What to Do About It.
.
https://articles.mercola.com/sites/articles/archive/2022/10/23/leland-stillman-new-health-care-system.aspx
WE ARE BEING SOLD | FAKE WAR! INFORMATION MISSING! BEHIND THE SCENE IN UKR & RUSS - TRUMP NEWS
Trump News Channel Published October 23, 2022
https://rumble.com/v1pff06-we-are-being-sold-fake-war-information-missing-behind-the-scene-in-ukr-and-.html
NATO WARNS “WAR WITH RUSSIA” //THOUSANDS OF TROOPS "READY TO CROSS BORDER”
Patriots Base Published October 23, 2022
https://rumble.com/v1pcx7y-nato-warns-war-with-russia-thousands-of-troops-ready-to-cross-border.html
SUNDAY LONG LIVE RADIO - WE'RE NOT GUNNA TAKE IT!
WATCH
https://www.bitchute.com/video/f5zKWCFL4Gbg/
HUGE ALBERTA PREMIER DANIELLE SMITH APOLOGIZES TO UNVACCINATED CITIZENS FOR SCUMBAGGERY
WATCH
https://www.bitchute.com/video/i8hXL5svs93i/
Armstrong in the Media Tags: Interview, Laura-Lynn Tyler ThompsonCheck out my
latest interview with Laura-Lynn Tyler Thompson.
https://www.armstrongeconomics.com/armstrong-in-the-media/interview-collapsing-global-finance-with-martin-armstrong/
WATCH LIVE: PRESIDENT DONALD J. TRUMP HOLDS SAVE AMERICA RALLY IN ROBSTOWN, TX 10/22/22
by RSBN
https://www.rsbnetwork.com/video/watch-live-president-donald-j-trump-holds-save-america-rally-in-robstown-tx-10-22-22/
Saturday, October 22, 2022: Join the RSBN broadcast team LIVE from Robstown, TX for all day coverage of President Donald J. Trump’s Save America rally.
President Donald J. Trump, 45th President of the United States of America, will hold a rally in Robstown, Texas on Saturday, October 22, 2022, at 7:00PM CDT.
Saturday, October 22, 2022, at 7:00PM CDT
President Donald J. Trump, 45th President of the United States of America, delivers remarks in support of his unprecedented effort to advance the MAGA agenda by energizing voters and highlighting the slate of 33-0 Trump Endorsed America First candidates in the Great State of Texas.
Additional Special Guest Speakers will be Announced.
JULIE GREEN PROPHETIC WORD [REVERSALS ARE COMING] CHANGE IS COMING - TRUMP NEWS
Trump News Channel Published October 15, 2022
https://rumble.com/v1o4gov-julie-green-prophetc-word-reversals-are-coming-change-is-coming-trump-news.html
OVERDUE FROM THE HAGUE. INTERNATIONAL TRIALS DAY ONE - NWO CRIMES AGAINST HUMANITY
WATCH
https://www.bitchute.com/video/GjEgSnACO93V/
Gold Standard Bargain; Aris Mining Corp.
https://www.aris-mining.com/operations/operating-mines/segovia/overview/default.aspx
https://www.aris-mining.com/investors/events-and-presentations/default.aspx
https://www.aris-mining.com/
Ted Butler: Stand up against market manipulation and make a difference
By Ted Butler
SilverSeek.com
Friday, October 14, 2022
If you are tired of witnessing silver (and gold) continuing to be manipulated in price, here's a no-cost, no-risk, high-potential return action you can take that will only involve a few minutes of your time. Quite literally, there's absolutely nothing to lose and quite a lot of potential good to be had.
The Commodity Futures Trading Commission is the taxpayer-funded federal commodities regulator whose main mission is to prevent and root out manipulation and protect the public. Four of the five commissioners have been in office for little more than six months and it's not clear that they are even aware that silver has been manipulated in price on the Comex.
Here is your opportunity to ensure that this is an issue they should be concerned about. Please take the time to copy and paste the letter below and email it to addresses listed. If you would prefer using your own name and not mine, you have my permission to do so. ...
... For the remainder of the commentary:
https://silverseek.com/article/stand-and-make-difference
https://www.aris-mining.com/operations/operating-mines/segovia/overview/default.aspx
https://www.aris-mining.com/investors/events-and-presentations/default.aspx
https://www.aris-mining.com/
GOD'S Money Bargain "Gold Standard Restoration Act" Would Peg Dollar To Gold At Fixed Price
28,398 views Oct 11, 2022
The Mother Of All Debt Bubbles Is About To
Preciouslife thanks; Big Pharma Set To Control Entire Food Supply
Patriots Base Published October 23, 2022
https://rumble.com/v1pel2j-big-pharma-set-to-control-entire-food-supply.html
Past and present thanks; ***Dr. Leland Stillman - How Conventional Medicine Kills, and What to Do About It.
.
https://articles.mercola.com/sites/articles/archive/2022/10/23/leland-stillman-new-health-care-system.aspx
WE ARE BEING SOLD | FAKE WAR! INFORMATION MISSING! BEHIND THE SCENE IN UKR & RUSS - TRUMP NEWS
Trump News Channel Published October 23, 2022
https://rumble.com/v1pff06-we-are-being-sold-fake-war-information-missing-behind-the-scene-in-ukr-and-.html
NATO WARNS “WAR WITH RUSSIA” //THOUSANDS OF TROOPS "READY TO CROSS BORDER”
Patriots Base Published October 23, 2022
https://rumble.com/v1pcx7y-nato-warns-war-with-russia-thousands-of-troops-ready-to-cross-border.html
SUNDAY LONG LIVE RADIO - WE'RE NOT GUNNA TAKE IT!
WATCH
https://www.bitchute.com/video/f5zKWCFL4Gbg/
HUGE ALBERTA PREMIER DANIELLE SMITH APOLOGIZES TO UNVACCINATED CITIZENS FOR SCUMBAGGERY
WATCH
https://www.bitchute.com/video/i8hXL5svs93i/
Armstrong in the Media Tags: Interview, Laura-Lynn Tyler ThompsonCheck out my
latest interview with Laura-Lynn Tyler Thompson.
https://www.armstrongeconomics.com/armstrong-in-the-media/interview-collapsing-global-finance-with-martin-armstrong/
WATCH LIVE: PRESIDENT DONALD J. TRUMP HOLDS SAVE AMERICA RALLY IN ROBSTOWN, TX 10/22/22
by RSBN
https://www.rsbnetwork.com/video/watch-live-president-donald-j-trump-holds-save-america-rally-in-robstown-tx-10-22-22/
Saturday, October 22, 2022: Join the RSBN broadcast team LIVE from Robstown, TX for all day coverage of President Donald J. Trump’s Save America rally.
President Donald J. Trump, 45th President of the United States of America, will hold a rally in Robstown, Texas on Saturday, October 22, 2022, at 7:00PM CDT.
Saturday, October 22, 2022, at 7:00PM CDT
President Donald J. Trump, 45th President of the United States of America, delivers remarks in support of his unprecedented effort to advance the MAGA agenda by energizing voters and highlighting the slate of 33-0 Trump Endorsed America First candidates in the Great State of Texas.
Additional Special Guest Speakers will be Announced.
JULIE GREEN PROPHETIC WORD [REVERSALS ARE COMING] CHANGE IS COMING - TRUMP NEWS
Trump News Channel Published October 15, 2022
https://rumble.com/v1o4gov-julie-green-prophetc-word-reversals-are-coming-change-is-coming-trump-news.html
OVERDUE FROM THE HAGUE. INTERNATIONAL TRIALS DAY ONE - NWO CRIMES AGAINST HUMANITY
WATCH
https://www.bitchute.com/video/GjEgSnACO93V/
Gold Standard Bargain; Aris Mining Corp.
https://www.aris-mining.com/operations/operating-mines/segovia/overview/default.aspx
https://www.aris-mining.com/investors/events-and-presentations/default.aspx
https://www.aris-mining.com/
Ted Butler: Stand up against market manipulation and make a difference
By Ted Butler
SilverSeek.com
Friday, October 14, 2022
If you are tired of witnessing silver (and gold) continuing to be manipulated in price, here's a no-cost, no-risk, high-potential return action you can take that will only involve a few minutes of your time. Quite literally, there's absolutely nothing to lose and quite a lot of potential good to be had.
The Commodity Futures Trading Commission is the taxpayer-funded federal commodities regulator whose main mission is to prevent and root out manipulation and protect the public. Four of the five commissioners have been in office for little more than six months and it's not clear that they are even aware that silver has been manipulated in price on the Comex.
Here is your opportunity to ensure that this is an issue they should be concerned about. Please take the time to copy and paste the letter below and email it to addresses listed. If you would prefer using your own name and not mine, you have my permission to do so. ...
... For the remainder of the commentary:
https://silverseek.com/article/stand-and-make-difference
https://www.aris-mining.com/operations/operating-mines/segovia/overview/default.aspx
https://www.aris-mining.com/investors/events-and-presentations/default.aspx
https://www.aris-mining.com/
GOD'S Money Bargain "Gold Standard Restoration Act" Would Peg Dollar To Gold At Fixed Price
28,398 views Oct 11, 2022
The Mother Of All Debt Bubbles Is About To
GREAT WATCH LIVE: PRESIDENT DONALD J. TRUMP HOLDS SAVE AMERICA RALLY IN ROBSTOWN, TX 10/22/22
by RSBN
https://www.rsbnetwork.com/video/watch-live-president-donald-j-trump-holds-save-america-rally-in-robstown-tx-10-22-22/
Saturday, October 22, 2022: Join the RSBN broadcast team LIVE from Robstown, TX for all day coverage of President Donald J. Trump’s Save America rally.
President Donald J. Trump, 45th President of the United States of America, will hold a rally in Robstown, Texas on Saturday, October 22, 2022, at 7:00PM CDT.
Saturday, October 22, 2022, at 7:00PM CDT
President Donald J. Trump, 45th President of the United States of America, delivers remarks in support of his unprecedented effort to advance the MAGA agenda by energizing voters and highlighting the slate of 33-0 Trump Endorsed America First candidates in the Great State of Texas.
Additional Special Guest Speakers will be Announced.
Venue:
Richard M. Borchard Regional Fairgrounds
1213 Terry Shamsie Blvd.
Robstown, TX 78380
Timeline of Events:
8:00AM – Parking Lots, Vendor Row, and Registration Open
2:00PM – Doors Open
4:00PM – Special Guest Speakers Deliver Remarks
7:00PM – 45th President of the United States Donald J. Trump Delivers Remarks
Entertainment and Concessions will be available throughout the day!
JULIE GREEN PROPHETIC WORD [REVERSALS ARE COMING] CHANGE IS COMING - TRUMP NEWS
Trump News Channel Published October 15, 2022
The Lords Day
https://rumble.com/v1p43dv-the-lords-day.html
https://rumble.com/v1o4gov-julie-green-prophetc-word-reversals-are-coming-change-is-coming-trump-news.html
OVERDUE FROM THE HAGUE. INTERNATIONAL TRIALS DAY ONE - NWO CRIMES AGAINST HUMANITY
WATCH
https://www.bitchute.com/video/GjEgSnACO93V/
Gold Standard Bargain; Aris Mining Corp.
https://www.aris-mining.com/operations/operating-mines/segovia/overview/default.aspx
https://www.aris-mining.com/investors/events-and-presentations/default.aspx
https://www.aris-mining.com/
Ted Butler: Stand up against market manipulation and make a difference
By Ted Butler
SilverSeek.com
Friday, October 14, 2022
If you are tired of witnessing silver (and gold) continuing to be manipulated in price, here's a no-cost, no-risk, high-potential return action you can take that will only involve a few minutes of your time. Quite literally, there's absolutely nothing to lose and quite a lot of potential good to be had.
The Commodity Futures Trading Commission is the taxpayer-funded federal commodities regulator whose main mission is to prevent and root out manipulation and protect the public. Four of the five commissioners have been in office for little more than six months and it's not clear that they are even aware that silver has been manipulated in price on the Comex.
Here is your opportunity to ensure that this is an issue they should be concerned about. Please take the time to copy and paste the letter below and email it to addresses listed. If you would prefer using your own name and not mine, you have my permission to do so. ...
... For the remainder of the commentary:
https://silverseek.com/article/stand-and-make-difference
https://www.aris-mining.com/operations/operating-mines/segovia/overview/default.aspx
https://www.aris-mining.com/investors/events-and-presentations/default.aspx
https://www.aris-mining.com/
GOD'S Money Bargain "Gold Standard Restoration Act" Would Peg Dollar To Gold At Fixed Price
28,398 views Oct 11, 2022
The Mother Of All Debt Bubbles Is About To
God Remedies; Dr. David Martin Calls For Prosecutions: Fauci Knew Remdesivir Would Kill Thousands
https://rumble.com/v1a7gwj-dr.-david-martin-calls-for-prosecutions-fauci-knew-remdesivir-would-kill-th.html
Breaking: Criminal Canadian Monopoly Dr. David Martin Exposes Why Trudeau Won't Back Down
https://sp.rmbl.ws/s8/1/x/p/X/e/xpXed.oq1b.2-small-Breaking-Criminal-Canadian-.jpg
700 Million Worldwide Will Die from CV19 Vax by 2028 – Dr. David Martin -
https://rumble.com/v1acoaa-up-to-100-million-will-die-from-cv19-vax-by-2028-dr-david-martin.html
Booster - bio killer jab; Why eight months? What's behind the timing of the Covid booster shot
New data about a third dose, expected from Biden federal officials as soon as
Wednesday, may be based on a dip in vaccine immunity seen in other countries,
experts said.
https://www.nbcnews.com/health/health-news/why-eight-months-what-s-behind-timing-covid-booster-shot-n1277013
TWO DOSES ARE NO LONGER ENOUGH': Canadians required to get COVID
shot every nine months
Author of the article:Denette Wilford
Publishing date:Jul 04, 2022 • Last Updated 22 hours ago •
https://torontosun.com/news/national/two-doses-are-no-longer-enough-canadians-required-to-get-covid-shot-every-nine-months/wcm/bae4cf26-f76c-46d4-ab49-ba9b9dfcb0c5/amp/
700 Million Worldwide Will Die from CV19 Vax by 2028 – Dr. David Martin - Greg Hunter Show - VIDEO
https://usawatchdog.com/up-to-700-million-worldwide-will-die-from-cv19-vax-by-2028-dr-david-martin/
High Level Pfizer Whistleblower Just Came Forward With Terrifying COVID
Announcement That Everyone Needs To See NOW
There’s not going to be any consistency, no matter what you look at. And then it
seems like a plethora of confusion is what they’re trying to levy against us so that
we can’t wade through this stuff so that we can’t understand it,” Townsend said.
https://americasfreedomfighters.com/pfizer-whistleblower/
Q - The Plan to Save the World - Trust The Plan
Patriot Movement Published July 4, 2022
https://rumble.com/v1b3gg9-q-the-plan-to-save-the-world-trust-the-plan.html
Happy Birthday America..
One in five COVID-19 survivors aged 18 – 64 years in the U.S. may have developed at least one condition linked to long COVID, a large new study conducted by the Centers for Disease Control and Prevention (CDC) indicates.
https://seekingalpha.com/news/3842706-long-covid-seen-with-one-in-five-covid-survivors-in-us-cdc-study?mailingid=27835564&messageid=2900&serial=27835564.44403
The prevalence is even higher among those aged 65 years and older, with one in four survivors showing at least one condition linked to previous coronavirus infection.
Long COVID is marked by hundreds of different symptoms such as fatigue, chest pain, and brain fog lasting more than three months.
The study based on electronic health record (EHR) data collected between March 2020–November 2021 looked for the occurrence of conditions often seen with long COVID.
Data, based on more than 350,000 COVID patients and over 1.6 million non-COVID patients, indicated that COVID survivors were twice as likely to develop pulmonary embolism or respiratory conditions.
In addition to preventative measures for COVID-19, the researchers noted routine screening for post COVID conditions as a critical tool to reduce the incidence of long COVID.
“It is sobering to see the results of this study again confirming the breadth of organ dysfunction and the scale of the problem," Dr. Ziyad Al-Aly, a clinical epidemiologist at Washington University in St. Louis, said.
The study results “can potentially translate into millions of people with new diabetes, heart disease, kidney disease, neurologic problems. These are lifelong conditions — certainly manageable, but not curable conditions,” The New York Times reported, quoting Dr. Al-Aly, who was not involved in the study.
With data indicating the serious long-term implications of COVID-19, “we need to develop additional tools to reduce the risk of long Covid,” he added.
COVID-19 vaccine maker Moderna (NASDAQ:MRNA) has donated its mRNA-based shot for use in a U.K.-based long COVID study, Reuters reported in March.
Pharma giants Pfizer (PFE) and Roche (OTCQX:RHHBY) (OTCQX:RHHBF) have reportedly shown interest in developing a cure for long COVID.
Developers of COVID-19 antibody drugs, GlaxoSmithKline (GSK), Vir Biotechnology (VIR), and Humanigen (HGEN), have discussed with researchers the potential of using their current medications in long COVID studies.
Look at the biotech indices YTD:
^IXIC
-24.54%
^NBI
-23.90%
^SPSIBI
-38.58%
THE BIOTECH ROUT HAS BEEN ACROSS THE BOARD AND DEVASTATING TO MANY COMPANIES WHOM ARE DOING WELL AND PROSPERING SO ARE NOW WAY OVERSOLD AND GREAT PROSPECTS GOING FORWARD IMHO
Monkeypox outbreak is primarily spreading through sex, WHO officials say https://www.cnbc.com/2022/05/23/monkeypox-outbreak-is-primarily-spreading-through-sex-who-officials-say.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
WHO confirms 80 cases of monkeypox with outbreaks in 11 countries https://www.cnbc.com/2022/05/20/world-health-organization-confirms-80-cases-of-monkeypox-with-outbreaks-in-11-countries.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
WHO confirms 80 cases of monkeypox with outbreaks in 11 countries https://www.cnbc.com/2022/05/20/world-health-organization-confirms-80-cases-of-monkeypox-with-outbreaks-in-11-countries.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Analysis: Should You Be Afraid Of A Monkeypox Pandemic?
Several stocks related to vaccines and pharmaceuticals moved on the news of the outbreak; here is a list of six.
Bavarian Nordic A/S - ADR
BVRNY Market cap: $810.95 million
Bavarian Nordic says it is highly specialized in researching, developing and manufacturing vaccines based on viral vectors to deliver antigens targeting infectious diseases and cancers.
More than that, Bavarian has built its foundation around poxviral-based vaccine platform technologies, particularly its proprietary technology, Modified Vaccinia Ankara – Bavarian Nordic (MVA-BN).
MVA-BN is approved as a smallpox vaccine in the U.S., Canada and the EU.
SIGA Technologies, Inc. SIGA
Market cap: $805.89 million
Siga Tech is a pharmaceutical company based in New York City that focuses on anti-viral smallpox treatment solutions.
The company’s leading product, Tecovirimat (Tpoxx), is an antiviral medication with activity against orthopoxviruses such as smallpox and monkeypox.
Siga was awarded a contract by the U.S Department of Defense on May 12 to produce approximately $7.5 million worth of the oral version of Tpoxx.
Chimerix Inc .. CMRX
Market cap: $205 million
Chimerix is a biopharmaceutical company that develops oral antiviral treatments, including Tembexa, a smallpox oral antiviral tablet approved by the FDA in 2021.
Emergent BioSolutions (see below) announced a deal with Chimerix on Monday to acquire exclusive rights to Tembexa.
Emergent Biosolutions Inc
EBS Market cap: $1.76 billion
Emergent is a multinational biopharmaceutical company that develops vaccines and antibody therapeutics for infectious diseases.
The company currently produces ACAM2000, a vaccine for smallpox and announced a deal to acquire Chimerix’s FDA-approved antiviral smallpox therapy.
Inovio Pharmaceuticals Inc .. INO
Market cap: $421.44 million
Inovio is a biotech company focused on discovering, developing and commercializing synthetic DNA products for treating cancers and infectious diseases.
In 2010, Inovio made news when it announced its smallpox DNA vaccine offered 100% protection in non-human primates against a highly pathogenic monkeypox challenge after vaccination.
Tonix Pharmaceuticals Holding Corp
NASDAQ: TNXP 52 week:0.088 - 2.59 Market cap: $47 million
Tonix is a pharmaceutical company based in New Jersey that focuses on repurposed drugs for central nervous system conditions.
Tonix is a producer of the TNX-801 vaccine, effective against smallpox and monkeypox.
Humanigen CEO DALE BOUGHT ANOTHER MILLION SHARES
Dale bought a million shares over the last 3 days. Looks like he might have also raised the share price to exactly $2.50 in afterhours trading so that he could exercise his calls. Things could get interesting if he continues to buy next week.
https://d18rn0p25nwr6d.cloudfront.net/CIK-0001293310/a080025c-f69e-4b1d-8e7f-5a8627f18620.pdf
The new May presentation is posted on Humanigen's site. Take a look at slide 15. In the group that had a CRP<150mg/L + <85yo + remdesivir, the mortality rate in the placebo arm was 17.3% and the mortality rate in the lenz arm was 7.5%. That is the exact group that is now the primary endpoint population of the ACTIV trial. That is bonkers mortality efficacy! Stat sig on mortality is possible or even likely in the ACTIV trial. Stat sig on mortality could push HGEN's share price north of $30!
https://s28.q4cdn.com/539885110/files/doc_presentations/2022/LSX-World-Congress-May-10-2022.pdf
Very interesting to hear Vanden Bossche make his case for focusing on infectiousness, versus hospitalization and death rates.
It basically completely overturns the thinking by Fauci and many others that lower hospitalizations and deaths signal an end to the pandemic.
Without bringing down the infectiousness of the virus, Vanden Bossche believes the worst is yet to come. I would recommend listening to minutes 25 - 28 (or better yet, 25-37) of the video.
Elsewhere, the alarm bells are ringing in China regarding the 'Zero Covid' policy they have implemented.
"China faces 'tsunami ' of 1.6 million deaths from omicron variant if Zero-COVID policy dropped: study
Published: May 11, 2022 at 2:59 a.m. ET
China's level of COVID immunity is not strong enough to fight an uncontrolled omicron epidemic, which could cause a "tsunami" of 1.55 million deaths if allowed to spread unchecked. That's according to a peer-reviewed report from Shanghai's Fudan University that published in the journal Nature on Tuesday. It comes as China faces criticism and anger from some locked-down citizens over the country's "Zero COVID" approach to virus control. "We find that the level of immunity induced by the March 2022 vaccination campaign would be insufficient to prevent an Omicron wave that would result in exceeding critical care capacity with a projected intensive care unit peak demand of 15.6-times the existing capacity and causing approximately 1.55 million deaths," the study's authors said. The country has seen progress in controlling the virus in major cities such as Shanghai, under lockdown in some places for a month. But officials there have warned relaxing measures too early would see the virus rebound. The head of the World Health Organization Tedros Adhanom Ghebreyesus this week criticized the country's strict policy as not sustainable.
https://www.marketwatch.com/story/china-faces-tsunami-of-16-million-deaths-from-omicron-variant-if-zero-covid-policy-dropped-study-2022-05-11?siteid=yhoof2
https://www.nature.com/articles/s41591-022-01855-7_reference.pdf
Polar opposite containment efforts in the US, versus China, and neither may be dialed-in to achieve success in overcoming the virus.
AWESOME, GREAT VIDEO AND FROM MINUTE 40 ON, SUCH TRUTH .....WOW, what a TRUTH VIDEO … THE REASON WHY MASS VACCINATIONS IS PERPETUATING THE VARIANTS … "40 MINUTE" ON >>
https://www.voiceforscienceandsolidarity.org/videos-and-interviews/geert-vanden-bossche-warns-the-vaccinated-of-immune-escape-variants
AWESOME, GREAT VIDEO AND FROM MINUTE 40 ON, SUCH TRUTH .....WOW, what a TRUTH VIDEO … THE REASON WHY MASS VACCINATIONS IS PERPETUATING THE VARIANTS … "40 MINUTE" ON >>
https://www.voiceforscienceandsolidarity.org/videos-and-interviews/geert-vanden-bossche-warns-the-vaccinated-of-immune-escape-variants
Pfizer to buy migraine drugmaker Biohaven in $11.6 billion deal https://www.cnbc.com/2022/05/10/pfizer-to-buy-biohaven-pharmaceutical-in-11point6-billion-deal.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Novavax (NVAX) – Novavax sank 23% in premarket trading after the vaccine maker missed both top and bottom line estimates for its latest quarter. The miss comes as Novavax shipped just 31 million Covid-19 vaccine doses during the quarter, putting it well off the pace of its projected 2 billion shots for 2022. Novavax reiterated its prior 2022 revenue forecast, however, saying it expected vaccine sales to accelerate during the current quarter.
Biohaven Pharmaceutical (BHVN) – The migraine drugmaker agreed to be bought by Pfizer (PFE) in a deal worth $11.6 billion, resulting in a 72% premarket surge in its shares. Biohaven shareholders will receive $148.50 per share in cash, plus half a share in a new publicly traded company that will hold some of the Biohaven drugs still in development. Pfizer, which had a 2.6% stake in Biohaven prior to the deal announcement, fell 1.4%.
Humanigen Reports First Quarter 2022 Financial Results
https://d18rn0p25nwr6d.cloudfront.net/CIK-0001293310/0edf9b05-002a-4178-b6e3-ca5ba6dd1c72.pdf
SHORT HILLS, N.J. May 5, 2022--(Business Wire)--
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate, lenzilumab (LENZ®), today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.
“A key highlight of the first quarter was the completion of enrollment in the ACTIV-5/BET-B study. We also held a productive Type B pre-EUA meeting with FDA where we gained alignment on the data and statistical analysis plan to be included as part of the amendment to our EUA for LENZ in COVID-19 patients. In concert with the NIH, we anticipate top-line data in the primary analysis population to be reported in the second quarter, with an amendment to our EUA submission planned to follow,” stated Cameron Durrant, Chairman and Chief Executive Officer, Humanigen. “We anticipate hospitalizations from COVID-19 will continue for years to come. Published data on LENZ, confirmed by key opinion leaders and national guideline committees, including NIH, supports treatment guidance based on CRP levels and first-line utilization in hypoxic patients.”
“Hospitalizations from COVID-19 in the US continue to remain steady with a 7-day average of 2,072 new daily hospitalizations. While there have been more than 900,000 people already hospitalized in the US this year to date, synergizing results from multiple forecasting models prepared by leading experts in epidemiology in four different scenarios forecast additional COVID-19 hospitalizations in the United States, to range from approximately 500,000 to 1,200,000 for the remainder of 2022. Variant agnostic treatments for hospitalized patients are still desperately needed,” commented Edward Jordan, Chief Commercial Officer, Humanigen.
“As well as its clinical benefit in reducing invasive mechanical ventilation and death, LENZ could deliver significant economic savings to health care systems. LENZ can be used in combination with remdesivir, which is currently used in 50% of hospitalized COVID-19 patients in the U.S. Sales of the top two hospital treatments for COVID-19 exceeded $7 billion in global revenue in 2021. We believe LENZ is well positioned to participate in this sizable and sustainable market,” he added.
Lenzilumab is an investigational product and is not currently authorized or approved in any country.
First Quarter and Recent Highlights: Lenzilumab in COVID-19 patients
· Completed enrollment of the Phase 2/3 ACTIV-5/BET-B study, sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and enrolled over 400 patients in the primary analysis population (patients with a C-reactive protein level at baseline of less than 150mg/L).
· Gained alignment with the FDA during a Type B pre-EUA meeting on the data and statistical analysis plan to be included in the amendment to the EUA.
· Announced a peer-reviewed publication in ClinicoEconomics and Outcomes Research outlining the potential clinical and health economic benefits of lenzilumab, if authorized or approved for use in the United Kingdom.
· First subject dosed in the PK study in Korea.
Lenzilumab in Development in Other Therapeutic Areas
· Gained alignment with the FDA on the protocol for the planned registrational Phase 3 SHIELD study of lenzilumab for the prevention of CAR-T therapy related toxicities including Immune Effector Cell-Associated Neurotoxicity (“ICANS”), in which Humanigen intends to enroll the first patient in the second quarter.
· Announced a peer-reviewed publication in Leukemia, a leading oncology and hematology journal, entitled “GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity.”
· Notified by the University of Birmingham, UK, that the amended Investigational Medicinal Product Dossier has been accepted by Medicines & Healthcare products Regulatory Agency for the “RATinG” study. Humanigen believes the first patient will be enrolled in this Phase 2/3 potentially registrational trial for lenzilumab to treat patients who have undergone allogeneic hematopoietic stem cell therapy, who are at high and intermediate risk for acute Graft versus Host Disease (“aGvHD”) in the second quarter.
· Continued enrollment in the PREACH-M study of lenzilumab in chronic myelomonocytic leukemia. Study sponsor planning for expansion of clinical
sites.
First Quarter Ended March 31, 2022 Financial Results
Net loss for the quarter ended March 31, 2022 was $21.3 million, or $0.32 per share, as compared to $65.6 million, or $1.25 per share, for the quarter ended
March 31, 2021. The decrease in net loss was due to a decrease in total expenses, mainly Research and Development (“R&D”) expense. R&D expense
decreased $42.7 million from $59.9 million for the three months ended March 31, 2021, to $17.2 million for the three months ended March 31, 2022. The
decrease is primarily due to a decrease of $35.7 million in lenzilumab manufacturing costs.
Cash and Cash Equivalents ....
Net cash used in operating activities, net of balance sheet changes, was $19.4 million for the quarter ended March 31, 2022. During the first quarter of 2022,
the company sold shares of its common stock under its At-the-Market or “ATM” facility, raising net proceeds of approximately $18 million. As of March 31, 2022, the company had cash and cash equivalents of approximately $69 million.
A summary of key financial highlights as of and for the three months ended March 31, 2022 and 2021 is as follows ($ in thousands):
In CAR-T, lenzilumab successfully achieved the pre-specified primary endpoint at the recommended dose in a Phase 1b study with Yescarta® in which the overall response rate was 100% and no patient experienced severe cytokine release syndrome or severe neurotoxicity. Based on these results, Humanigen plans to test lenzilumab in a randomized, multicenter, potentially registrational, Phase 3 SHIELD study to evaluate its efficacy and safety when combined with Yescarta and Tecartus® CAR-T therapies in non-Hodgkin lymphoma. Lenzilumab will also be tested to assess its ability to prevent and/or treat aGvHD in patients undergoing allogeneic hematopoietic stem cell transplantation.
A study of lenzilumab is also underway for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. This study builds on evidence from a Phase 1 study, conducted by Humanigen, that showed RAS mutations are associated with hyper-proliferative features, which may be sensitive to GMCSF neutralization.
Israeli researchers warn of new international COVID wave, driven by Delta comeback
Omicron didn’t wipe out the previous variant, which is super-resilient and could reemerge with a vengeance, according to peer-reviewed study based on cutting-edge sewage monitoring
https://www.timesofisrael.com/israeli-researchers-warn-of-new-international-covid-wave-driven-by-delta-comeback/amp/
There is a real danger of another international COVID wave this summer, with the Delta variant possibly poised to make a comeback, new Israeli research suggests.
The peer-reviewed study is based on cutting-edge Israeli monitoring of sewage, which reveals not only the prevalence of coronavirus cases, but also their variant.
It showed that even at the height of the Omicron wave, the previous Delta variant hadn’t been wiped out, even though it was expected to be based on the dynamics of previous waves.
After monitoring the patterns of the two variants, the researchers concluded that Omicron and its subvariants are likely to disappear soon, but Delta has shown such strong resilience that it could well reemerge.
“Our findings highlight that the pandemic is not over and suggest that sooner or later there will be another wave, potentially in the summer or at the end of the summer,” Prof. Ariel Kushmaro, who runs the Ben-Gurion University of the Negev wastewater lab that conducted the research, told The Times of Israel.
He said that the significance extends far beyond Israel, and indicated that internationally, Delta still poses a larger threat than widely assumed. Delta could reemerge in its existing form, or could spread in the form of a new subvariant, he predicted.
Some COVID experts say that the study gives a clear basis in data for a warning they have been giving for weeks.
“The pandemic isn’t over, and this great piece of research provides clear findings that emphasize this and help us to understand the situation,” immunologist Dr. Yariv Wine, a Tel Aviv University academic who wasn’t involved in theBen-Gurion research, told The Times of Israel.
Kushmaro said that Delta’s resilience surprised his team. “In the past, we saw that when one variant rises, others disappear; but this just doesn’t seem to have happened with Delta, which seems to have a certain ability to survive,” he said.
“In this study, we identified that even when Omicron was at its very highest in the wastewater, Delta was still circulating,” he added. “The patterns we see indicate that Omicron is in demise, but Delta has survived and is positioned to possibly reemerge.”
Kushmaro and his colleagues, including Dr. Karin Yaniv, wrote that according to their analysis model Delta is expected to continue to circulate largely undetected — what they call cryptic circulation — until it causes a wave. They published their findings in the journal Science of the Total Environment.
“According to the developed model, it can be expected that the Omicron levels will decrease until eliminated, while Delta variant will maintain its cryptic circulation,” they wrote. “If this comes to pass, the mentioned cryptic circulation may result in the reemergence of a Delta morbidity wave or in the possible generation of a new threatening variant.”
CDC says adenovirus may have caused Alabama outbreak of severe hepatitis in kids https://www.cnbc.com/2022/04/29/cdc-says-adenovirus-may-contribute-to-liver-injury-in-healthy-children.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Denmark becomes the first country to halt its Covid vaccination program https://www.cnbc.com/2022/04/28/denmark-the-first-country-to-halt-its-covid-vaccination-program.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
1/ UHOH: cases in South Africa DOUBLING IN A WEEK starting to hit exponential rise with BA4 variant quickly dominating: BA4 is a recombinant of BA1 + BA2 & contains the deadly L452R Delta spike mutation: it's a Deltacron on steroids and climbing fast. pic.twitter.com/r4pXWZezJa
— Chris Turnbull (@EnemyInAState) April 28, 2022
Merck sold $3.2 billion of its Covid oral antiviral treatment in first-quarter https://www.cnbc.com/2022/04/28/merck-mrk-earnings-q1-2022.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
GM-CSF Knock-out CAR-T Study Published in Peer-Reviewed Journal Leukemia
https://ir.humanigen.com/English/news/news-details/2022/GM-CSF-Knock-out-CAR-T-Study-Published-in-Peer-Reviewed-Journal-Leukemia/default.aspx
-CRISPR/Cas9-Mediated GM-CSF knock-out (GM-CSFko) CAR-T cells demonstrate reduced apoptosis and enhanced in vivo anti-tumor activity in preclinical models
-Phase 3 SHIELD study utilizing lenzilumab to prophylactically neutralize GM-CSF in CAR-T to begin 1H22
SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today a peer-reviewed publication in Leukemia, a leading oncology and hematology journal, entitled “GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity.”
This publication is a significant addition to the findings from a previous article in the leading hematology journal, blood, which demonstrated that neutralization of GM-CSF with lenzilumab (LENZ®) was able to break the efficacy/toxicity linkage by reducing cytokine release syndrome (CRS) and neuroinflammation (ICANS) while enhancing CAR-T function.1 The Leukemia publication demonstrates that CRISPR/Cas9-mediated GM-CSF knockout in CAR-T cells directly ameliorates CAR-T cell early activation, reduces activation-induced cell death, and results in enhanced anti-tumor activity in vivo in a xenograft model.2
Enhancing CAR-T cell in vivo efficacy by using strategies to non-specifically stimulate CAR-T cell proliferation utilizing synthetic biology or combination therapy to edit exhaustion pathways or prevent apoptosis is an important goal and is the subject of substantial ongoing research. However, while this may improve CAR-T efficacy, it is often at the cost of an increase in important toxicities, such as CRS and ICANS. In contrast, these data published in Leukemia indicate that GM-CSko CAR-T cells result in enhanced CAR-T cell proliferation and anti-tumor activity while being associated with a marked reduction in GM-CSF levels, which have been linked to CAR-T associated toxicities.
CAR-T therapies have resulted in significant advances for patients. However, for up to one-third of patients, toxicities such as severe ICANS and CRS occur, and tumor relapse is still a frequent occurrence.3 Currently, the widespread adoption of CAR-T therapy is limited, in part, by the requirement for treatment in centers that are experienced in managing the common toxicities of ICANS and CRS and by the financial and health burden that this creates. “CRS, ICANS, and tumor relapse remain challenges for physicians and patients treated with CAR-T therapy,” said Saad Kenderian, M.B., Ch.B., hematologist at Mayo Clinic Cancer Center, an author of the Leukemia paper and the primary investigator for the SHIELD study (Study on How to Improve Efficacy and toxicity with Lenzilumab in DLBCL and other NHL patients treated with CAR-T therapy). He added, “They result in additional morbidity for patients, as well as significantly increased costs for healthcare providers. Treatments that can prevent ICANS and CRS while potentially improving CAR-T efficacy could address a critical unmet need.”
This publication adds to the body of knowledge of GM-CSF depletion in CAR-T. The upcoming Phase 3 CAR-T study, known as SHIELD, will determine the efficacy and safety of prophylactic lenzilumab on the rates of ICANS, CRS, and CAR-T efficacy. “The SHIELD trial has been designed to build on the positive results from the ZUMA-19 study. The primary endpoint of SHIELD will focus on demonstrating a significant improvement in neurotoxicity associated with both Yescarta® and Tecartus®. We will also seek to explore the beneficial impact that lenzilumab may have CAR-T efficacy,” stated Dale Chappell, M.D., MBA, Chief Scientific Officer, Humanigen.
Novavax: Vaccine targeting Covid and flu shows promising results in early data https://www.cnbc.com/2022/04/20/novavax-says-vaccine-targeting-covid-and-flu-shows-promising-results-in-early-data.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS
https://ir.humanigen.com/English/news/news-details/2022/Humanigen-Announces-Peer-Reviewed-Publication-Demonstrating-the-Potential-Clinical-and-Economic-Benefits-of-Lenzilumab-from-the-Perspective-of-the-NHS/default.aspx
-In a weekly cohort of 4,754 newly hospitalized patients, addition of lenzilumab to standard of care (SOC) could result in over £5.5 million in cost savings weekly
-Lenzilumab plus SOC resulted in per-patient cost savings between £8,462 and £17,277 (net savings of £1,162 - £9,977) depending on patient population
-The number of COVID-19 cases continues to remain high with approximately 20,000 patients currently hospitalized in the UK,2 demonstrating the urgent need for both clinically effective and cost-effective variant-agnostic treatments for hospitalized patients
SHORT HILLS, N. J.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced a peer-reviewed publication in ClinicoEconomics and Outcomes Research outlining the potential clinical and health economic benefits of lenzilumab, if authorized or approved for use in the United Kingdom.
“As COVID-19 continues to place significant burden on the National Health Service (“NHS”), this paper demonstrates there is an opportunity to realize significant cost savings for healthcare systems of the UK while improving outcomes for patients. As a variant-agnostic treatment, lenzilumab may offer both a clinically effective and cost-effective option against current and emerging variants,” said Adrian Kilcoyne, M.D., Chief Medical Officer, Humanigen, the lead author of the publication.
The publication demonstrated, in all cases, lenzilumab plus SOC improved all specified clinical outcomes compared with SOC alone. Additionally, patient selection, utilizing CRP<150 mg/L as a biomarker, optimized both clinical and economic outcomes.The observed cost savings are mainly driven by fewer bed days, days on invasive mechanical ventilation and ICU days.
The greatest per-patient cost savings were for patients aged <85 years, CRP <150 mg/L, and receiving remdesivir of £10,427 (net savings of £3,127 after expected lenzilumab acquisition costs); and for Black patients with CRP <150 mg/L of £17,277 (net savings of £9,977).
“During these unprecedented and challenging times, we are preparing to commercialize lenzilumab, if authorized or approved, as a single day treatment and a potential driver of clinical and economic value to patients and the healthcare system,” said Edward Jordan, Chief Commercial Officer, Humanigen.
This peer-reviewed publication highlights the significant costs of treating hospitalized COVID-19 patients and the economic benefits of potentially improving survival without ventilation, reducing ventilator use, hospital days and ICU days which may be associated with adding lenzilumab to standard of care.
Followers
|
44
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5468
|
Created
|
10/11/07
|
Type
|
Premium
|
Moderator Preciouslife1 | |||
Assistants toddao kgoodrich |
This board is about medical news, medical and medicine advancements from pharmaceutical and biotech companies, as
well as Universities. Company explicit news is welcomed as
well as industry news. This is an information sharing board,
where the latest and newest medical related information can
be posted and disseminated. Enjoy your board...
Scientific and Medical dedicated Search engine:
http://www.scirus.com/srsapp/
http://science.howstuffworks.com/dna.htm
http://www.biologicdrugreport.com/
Naming convention for antibody suffixes:
-ximab = chimeric
-zumab = humanized
-(~z)umab = fully human
FDA and CDC sites:
FDA what's new site: http://www.fda.gov/ohrms/dockets/ac/acwhatsnew.htm
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
http://www.fda.gov/
http://www.fda.gov/cder/
http://news.google.com/news?q=FDA&hl=en&rls=DGUS,DGUS:2006-15,DGUS:en&um=1&ie=UTF-8&....
http://www.cdc.gov/
Researching sites:
http://clearstation.etrade.com/
http://www.breakouttrading.net/index2/index.php
http://moneycentral.msn.com/investor/home.asp
http://www.superstarinvestor.com/directory.html
http://www.nasdaq.com/
http://www.ddmachine.com/default.asp
http://new.stockwatch.com/
http://www.edgar-online.com/
Educational sites:
http://www.investopedia.com/
http://www.qwoter.com/college/
http://biotech-profits.org/
http://www.hardrightedge.com/wheel/tcrules1.htm
http://www.therapeuticsdaily.com/news/channel.cfm?channelID=28
http://www.medicalnewstoday.com/sections/genetics/
http://www.medicalnewstoday.com/sections/biology-biochemistry/
http://content.nejm.org/current.shtml
http://www.sciencedaily.com/
Some T/A sites:
http://www.americanbulls.com/
http://www.askresearch.com/
http://www.stockta.com/
http://www.stockconsultant.com./
http://www.investorshub.com/boards/read_msg.asp?message_id=297509
http://www.ttrader.com/dirttime.php
http://www.otcbb.com/asp/Info_Center.asp
http://bigcharts.marketwatch.com/
Find out if your stock is on the SHO List
http://www.buyins.net/tools/short_list.php?src=1,7,9
Understanding Level 11-http://www.hotstockmarket.com/forums/showthread.php?t=14938
OTCBB Biggest Gainers (%)http://www.stockhouse.com/mostactives/index.asp?type=winners&exchange=OTCBB
OTC Biggest Declinershttp://www.stockhouse.com/mostactives/index.asp?type=losers&exchange=OTCBB
OTC Biggest Volume Gainers http://www.stockhouse.com/mostactives/index.asp?type=mostactives&exchange=OTCBB
Technical Indicators http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators
Screeners:
http://finviz.com/screener.ashx?v=111&f=cap_microover,geo_usa,sh_curvol_o100,sh_insttrans_o20,sh_price_o1,sh_short_u5,ta_rsi_ob70&ft=4&r=21 From Stock Seasonality Site.
http://www.marketscreen.com/c/pcquote/default.asp
http://moneycentral.msn.com/investor/finder/deluxestockscreen.aspx?query=Institutional+Ownership+Up+....
http://www.secform4.com/index.php
http://screen.morningstar.com/StockSelector.html
http://www.stockfetcher.com
http://investorideas.com/
http://www.wallstreettape.com/
http://findarticles.com/p/articles/mi_pwwi/is_200603/ai_n1610669
4
http://find.thestreet.com/cgi-bin/texis/tscsection/?k=Technology&sec=Technology&submenu=news....
Filings Sites:
http://www.pinksheets.com/
http://www.otcbb.com
http://www.gsionline.com/support/formtypes.html
http://www.coordinatedlegal.com/SecretaryOfState.html
http://www.searchsystems.net/list.php?nid=398
SEC FORM EXPLANATIONS
http://www.sec.gov/about/forms/secforms.htm
http://www.briefing.com/GeneralInfo/Features/LearningCenter/edu_SEC_Documents.htm
http://www.sec.gov/index.htm
To see how and about the SEC rules, regulations and cases involving stock manipulators.
SEC REALTIME FILINGS
http://www.nasdaq.com/asp/quotes_sec.asp?mode=&page=&symbol=QQQQ&symbol=&symbol=&....
http://home.businesswire.com/portal/site/home/index.jsp?front_door=true&headlineSearchConfigBO=v....
BOARD RULES:
The main objective for this moderated thread is to keep it free of posts which do not add value to the discussion of the stocks, the latest medical news, and information, while keeping the board balanced, clean, on-topic with due diligence kept up to date.
All posts here should stay focused on medical news and information.
Pro and con debate is encouraged as long as the opinions are kept on a mature level, with the omission of personal attacks,
violations of IHUB rules and basic civility.
Personal attacks, personal issues, political innuendo, spamming, duplicate posts of same subject matter, redundancy, obvious bashing, blatant pumping, irrelevant off topic subject matter, advertising, arguing, feeding and promoting bashers of other IHUB sites will be strictly prohibited.
Posts which the moderators feel violate these rules will be removed without question or debate.
If you are willing to cooperate and co~exist with other posters in this environment within the guidelines laid out, then welcome and have a great time posting and learning.
Please Note: Please add links to websites and information whenever they are available for accuracy and informational purposes.
Plus, I am not an MD, but rather a longtime biotech/pharma investor and former Quant analyst. So, if I can answer any questions relating to medical information, I will, and cede to any medical professionals whom are better equipped to answer those inquiries.
Thank you....PL1
Posts Today
|
0
|
Posts (Total)
|
5468
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |